<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00204542</url>
  </required_header>
  <id_info>
    <org_study_id>ADO-Solaraze-AK-3-6</org_study_id>
    <secondary_id>Eudra-CT-Nr. 2004-002761-21</secondary_id>
    <nct_id>NCT00204542</nct_id>
  </id_info>
  <brief_title>Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head</brief_title>
  <official_title>Comparison of the Efficacy and Tolerability of Solaraze for 3 vs. 6 Months in Patients With Mild to Moderate Actinic Keratosis Located at the Face and Head</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <brief_summary>
    <textblock>
      Topical treatment of mild to moderate actinic keratosis located on the face and head with
      Solaraze® is known to be a safe and efficient treatment option. However, it is unclear if an
      expansion of the treatment period to 6 months will increase the rate of complete responses.

      Therefore the investigators will evaluate the efficacy and safety of the treatment of actinic
      keratosis with Solaraze® applied twice daily to the face and head over 3 or 6 months of
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histologically controlled complete clearance of the actinic keratosis</measure>
    <time_frame>6 weeks after end of treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">418</enrollment>
  <condition>Photosensitivity Disorders</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Solaraze(R) 2x/day for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Solaraze(R) 2x/day for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac</intervention_name>
    <description>Solaraze® (Diclofenac sodium) 2x/day topical for 3 months</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac</intervention_name>
    <description>Solaraze® (Diclofenac sodium) 2x/day topical for 6 months</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Visible and histologically proven actinic keratosis

          -  Prepared and able to give written informed consent

          -  ≥ 18 -80 years of age

          -  Prepared and comply with all study requirements, including the following: application
             of gel on the treatment area twice a day, 5 / 7 clinic visits during the prestudy,
             treatment, posttreatment, and follow-up period

          -  Pre- and posttreatment biopsy for histological confirmation (of clearance) of actinic
             keratosis diagnosis

        Exclusion Criteria:

          -  Data of clinically significant, unstable, cardiovascular or haematologic, hepatic,
             neurologic, renal, endocrine, collagen-vascular, or gastrointestinal abnormalities or
             diseases

          -  Known allergies to any excipient in the study drug

          -  Any dermatological disease and/or condition in the treatment or surrounding area (3 cm
             distances from treatment area) that may be exacerbated by treatment with diclofenac or
             cause difficulty with examination

          -  Active chemical dependency or alcoholism, as assessed by the investigator

          -  Currently participating in another clinical study or have completed another clinical
             study with an investigational drug within the past 30 days

          -  Received topical treatment at the treatment area with imiquimod or 5-FU within a time
             period of 1 month

          -  Invasive tumours within the treatment area, e.g. merkel cell carcinoma, squamous cell
             carcinoma, basal cell carcinoma, the latter is accepted if completely surgically
             removed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus Garbe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skin Cancer Program, Department of Dermatology, University Hospital Tübingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skin Cancer Program, Department of Dermatology, Liebermeisterstrasse 8</name>
      <address>
        <city>Tübingen</city>
        <state>BW</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik fuer Dermatologie, Venerologie und Allergologie der Charite</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Dermatology</name>
      <address>
        <city>Freiburg</city>
        <zip>79104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Priv.-Doz. Dr. med. Dirschka</name>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/21414035</url>
    <description>Link to published abstract</description>
  </link>
  <reference>
    <citation>Nelson C, Rigel D, Smith S, Swanson N, Wolf J. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol. 2004 Jul-Aug;3(4):401-7.</citation>
    <PMID>15303784</PMID>
  </reference>
  <reference>
    <citation>Rivers JK. Topical 3% diclofenac in 2.5% hyaluronan gel for the treatment of actinic keratoses. Skin Therapy Lett. 2004 Jan;9(1):1-3.</citation>
    <PMID>14716439</PMID>
  </reference>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>August 18, 2011</last_update_submitted>
  <last_update_submitted_qc>August 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Claus Garbe</name_title>
    <organization>DECOG</organization>
  </responsible_party>
  <keyword>actinic keratosis</keyword>
  <keyword>diclofenac sodium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Photosensitivity Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

